Rebooting the healthcare system post-COVID-19Janssen’s Iris Zemzoum looks at seven ways the healthcare and pharma sectors need to change in the wake Share XRebooting the healthcare system post-COVID-19https://pharmaphorum.com/views-analysis-digital/rebooting-the-healthcare-system-post-covid-19/
Investing in innovation – new digital approaches for a new decade For the first time in history, we have the technologies that will allow us to develop new Share XInvesting in innovation – new digital approaches for a new decadehttps://pharmaphorum.com/views-analysis-digital/investing-in-innovation-new-digital-approaches-for-a-new-decade/
Janssen’s Gaëtan Leblay on leading during the COVID-19 crisisCOVID-19 is putting unimaginable pressure on healthcare systems and the companies looking for solutions to end the pandemic. Share XJanssen’s Gaëtan Leblay on leading during the COVID-19 crisishttps://pharmaphorum.com/r-d/views-analysis-r-d/janssens-gaetan-leblay-on-leading-during-the-covid-19-crisis/
J&J strengthens R&D into COVID-19 vaccine with US governmentJohnson & Johnson has announced it has expanded a collaboration with a US government agency to hasten development Share XJ&J strengthens R&D into COVID-19 vaccine with US governmenthttps://pharmaphorum.com/news/jj-strengthens-rd-into-covid-19-vaccine-with-us-government/
3 key trends shaping the immunology marketFrom an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an Share X3 key trends shaping the immunology markethttps://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/
Has pharma been too slow to respond to coronavirus?The new coronavirus strain emerging in China is making headlines across the world, with the disease sending entire Share XHas pharma been too slow to respond to coronavirus?https://pharmaphorum.com/r-d/views-analysis-r-d/has-pharma-been-too-slow-to-respond-to-coronavirus/
J&J brushes off concerns over talc, opioid and Risperdal litigationJohnson & Johnson has brushed off investors’ concerns over the many lawsuits it is facing, saying its legal Share XJ&J brushes off concerns over talc, opioid and Risperdal litigationhttps://pharmaphorum.com/news/jj-brushes-off-concerns-over-litigation/
US court tells J&J to pay $8bn damages to man over breast growthA court has told Johnson & Johnson to pay $8 billion in punitive damages to a man who Share XUS court tells J&J to pay $8bn damages to man over breast growthhttps://pharmaphorum.com/news/us-court-tells-jj-to-pay-8bn-damages-to-man-over-breast-growth/
Making behaviour change stickBehaviour change is set to become a key skill for pharma companies in the very near future – Share XMaking behaviour change stickhttps://pharmaphorum.com/digital/making-behaviour-change-stick/
